These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Garcia-Manero G; Goldberg AD; Winer ES; Altman JK; Fathi AT; Odenike O; Roboz GJ; Sweet K; Miller C; Wennborg A; Hickman DK; Kanagal-Shamanna R; Kantarjian H; Lancet J; Komrokji R; Attar EC; Sallman DA Lancet Haematol; 2023 Apr; 10(4):e272-e283. PubMed ID: 36990622 [TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108 [TBL] [Abstract][Full Text] [Related]
6. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Welch JS; Petti AA; Miller CA; Fronick CC; O'Laughlin M; Fulton RS; Wilson RK; Baty JD; Duncavage EJ; Tandon B; Lee YS; Wartman LD; Uy GL; Ghobadi A; Tomasson MH; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Cashen AF; Schroeder MA; Jacoby MA; Heath SE; Luber K; Janke MR; Hantel A; Khan N; Sukhanova MJ; Knoebel RW; Stock W; Graubert TA; Walter MJ; Westervelt P; Link DC; DiPersio JF; Ley TJ N Engl J Med; 2016 Nov; 375(21):2023-2036. PubMed ID: 27959731 [TBL] [Abstract][Full Text] [Related]
7. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. Short NJ; Muftuoglu M; Ong F; Nasr L; Macaron W; Montalban-Bravo G; Alvarado Y; Basyal M; Daver N; Dinardo CD; Borthakur G; Jain N; Ohanian M; Jabbour E; Issa GC; Qiao W; Huang X; Kanagal-Shamanna R; Patel KP; Bose P; Ravandi F; Delumpa R; Abramova R; Garcia-Manero G; Andreeff M; Cortes J; Kantarjian H J Hematol Oncol; 2023 Jul; 16(1):73. PubMed ID: 37422688 [TBL] [Abstract][Full Text] [Related]
8. Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia. Cluzeau T; Loschi M; Fenaux P; Komrokji R; Sallman DA Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576266 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Bally C; Adès L; Renneville A; Sebert M; Eclache V; Preudhomme C; Mozziconacci MJ; de The H; Lehmann-Che J; Fenaux P Leuk Res; 2014 Jul; 38(7):751-5. PubMed ID: 24836762 [TBL] [Abstract][Full Text] [Related]
11. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment. Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086 [TBL] [Abstract][Full Text] [Related]
12. Santini V; Stahl M; Sallman DA Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432650. PubMed ID: 38768424 [No Abstract] [Full Text] [Related]
13. Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS. Mawad R; Becker PS; Hendrie P; Scott B; Wood BL; Dean C; Sandhu V; Deeg HJ; Walter R; Wang L; Myint H; Singer JW; Estey E; Pagel JM Br J Haematol; 2016 Jan; 172(2):238-45. PubMed ID: 26568032 [TBL] [Abstract][Full Text] [Related]
14. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503 [TBL] [Abstract][Full Text] [Related]
15. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively. Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886 [TBL] [Abstract][Full Text] [Related]
16. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. Sallman DA; Al Malki MM; Asch AS; Wang ES; Jurcic JG; Bradley TJ; Flinn IW; Pollyea DA; Kambhampati S; Tanaka TN; Zeidner JF; Garcia-Manero G; Jeyakumar D; Komrokji R; Lancet J; Kantarjian HM; Gu L; Zhang Y; Tan A; Chao M; O'Hear C; Ramsingh G; Lal I; Vyas P; Daver NG J Clin Oncol; 2023 May; 41(15):2815-2826. PubMed ID: 36888930 [TBL] [Abstract][Full Text] [Related]
17. A systematic review and meta Kunacheewa C; Thongthang P; Ungprasert P; Utchariyaprasit E; Owattanapanich W Hematology; 2019 Dec; 24(1):498-506. PubMed ID: 31221030 [TBL] [Abstract][Full Text] [Related]
18. Azacitidine combined with venetoclax alleviates AML-MR with TP53 mutation in SDS: a case report and literature review. Ma C; Lang H; Chen Y; Yang L; Wang C; Han L; Chen X; Ma W Anticancer Drugs; 2024 Jul; 35(6):548-555. PubMed ID: 38502829 [TBL] [Abstract][Full Text] [Related]
19. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis. Liu W; Zhou Z; Chen L; Wang X Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056 [TBL] [Abstract][Full Text] [Related]